The rapidly developing field of personalized or precision medicine is moving clinical practice towards a new paradigm centred on ‘right patient – right medication – right time'. Such information is obtained through analysis of biomarkers, usually specific proteins or DNA sequences. To expand the range of conditions in which a precision approach can be used, it is vital that new biomarkers continue to be discovered and qualified as having clinical utility. Once this is achieved, it is just as important that clinically validated assays to measure these biomarkers are made available to clinical groups to guide prescribing practice.

This content is only available as a PDF.